Date: 2013-06-25
Type of information: Development agreement
Compound: reparixin
Company: Dompé (Italy) SatRx (Russia)
Therapeutic area: Transplantation
Type agreement: development
Action mechanism: Reparixin is a potent selective chemokine interleukin-8 inhibitor developed by Dompè Italian R&D laboratories. Reparixin is an inhibitor of the CXCR1 receptor which in the body is activated by chemokine interleukin-8 that plays a key role in anti-inflammatory response. It is the first in a novel class of low-molecular weight inhibitors that can selectively modulate the receptor activity via an allosteric mechanism of action. An allosteric inhibitor can freeze the receptor in an inactive position binding it to a different site than the site taken by the natural ligand (IL-8).
Disease: prevention of early allograft dysfunction in liver transplanted patients
Details: * On June 25, 2013, Dompé, one of Italy\'s leading biopharmaceutical companies, and SatRx, a Russian biotechnology company specialised on the development of innovative medicines used in solid organ transplantation and for the treatment of metabolic diseases, have signed a collaboration agreement for the clinical development of reparixin, an innovative drug discovered by Dompé to improve efficacy of liver transplantation. The alliance between the companies focuses on Phase II-III clinical trials which are the final stages of clinical development prior to drug marketing. The international multi-center randomized Phase III trial to assess efficacy of reparixin in islet transplantation is lead by Dompe. The multi-center, open-label, randomized Phase II-III trials are prepared to assess the efficacy and safety of reparixin in the prevention of early allograft dysfunction in liver transplanted patients. Patients for liver transplantation will be recruited into the clinical trial that is scheduled to start in September 2013. Reparixin is expected to be officially launched in the Russian market in 2016.
Made under The Strategy of Development of the Pharmaceutical Industry of the Russian Federation (\"Pharma 2020 Strategy\") programme that Ministry of Industry and Trade of The Russian Federation has sponsored since 2009, the alliance lays the groundwork for a new indication for Reparixin, and confirms Dompé as a vibrant group with excellent prospects. The \"Pharma 2020 Strategy\" programme aims at boosting the competitiveness and innovativeness of the Russian pharmaceutical industry both in terms of R&D and production. This important development program is generating in the country a sort of positive \"flywheel\" that is attracting major pharmaceutical groups around the world, with the goal of creating partnerships that allow a steady growth of pharmaceutical R&D and production in Russia.
Financial terms:
Latest news:
